Minimal Residual Disease Monitoring in Acute Myeloid Leukemia with Non-A/B/D-NPM1 Mutations by Digital Polymerase Chain Reaction: Feasibility and Clinical Use

Overview

Journal Haematologica

Specialty Hematology

Date 2020 Dec 10

PMID 33299234

Citations 6

Authors

Auriane Lesieur

Xavier Thomas

Olivier Nibourel

Nicolas Boissel

Laurene Fenwarth

Stephane de Botton

Elise Fournier

Karine Celli-Lebras

Emmanuel Raffoux

Christian Recher

Juliette Lambert

Celine Berthon

Arnaud Pigneux

Raphael Itzykson

Pascal Turlure

Cecile Pautas

Jacques Vargaftig

Claude Preudhomme

Herve Dombret

Nicolas Duployez

Affiliations

Soon will be listed here.

Abstract

Not available.

Citing Articles

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.

Gang M, Othus M, Walter R Cells. 2025; 14(4).

PMID: 39996762 PMC: 11853423. DOI: 10.3390/cells14040290.

Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia.

Zhao Z, Lan J Ann Hematol. 2024; 103(12):4869-4881.

PMID: 39283479 DOI: 10.1007/s00277-024-06008-z.

Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.

Chea M, Rigolot L, Canali A, Vergez F Int J Mol Sci. 2024; 25(4).

PMID: 38396825 PMC: 10889505. DOI: 10.3390/ijms25042150.

Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AML.

Falini B, Dillon R Blood Cancer Discov. 2023; 5(1):8-20.

PMID: 37917833 PMC: 10772525. DOI: 10.1158/2643-3230.BCD-23-0144.

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.

Vasseur L, Fenwarth L, Lambert J, de Botton S, Figeac M, Villenet C Blood Adv. 2023; 7(15):4024-4034.

PMID: 37205853 PMC: 10410128. DOI: 10.1182/bloodadvances.2023010155.

References

Falini B, Nicoletti I, Martelli M, Mecucci C . Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2006; 109(3):874-85. DOI: 10.1182/blood-2006-07-012252. View

Svec D, Tichopad A, Novosadova V, Pfaffl M, Kubista M . How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments. Biomol Detect Quantif. 2016; 3:9-16. PMC: 4822216. DOI: 10.1016/j.bdq.2015.01.005. View

Grimwade D, Jovanovic J, Hills R, Nugent E, Patel Y, Flora R . Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009; 27(22):3650-8. DOI: 10.1200/JCO.2008.20.1533. View

Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A . Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016; 374(5):422-33. DOI: 10.1056/NEJMoa1507471. View

Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A . Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol. 2017; 35(2):185-193. DOI: 10.1200/JCO.2016.67.1875. View

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum F, Buchner T . Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016; 129(4):424-447. PMC: 5291965. DOI: 10.1182/blood-2016-08-733196. View

Paietta E . Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program. 2012; 2012:35-42. DOI: 10.1182/asheducation-2012.1.35. View

Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P . Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013; 121(12):2213-23. DOI: 10.1182/blood-2012-10-462879. View

Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W . Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. Haematologica. 2015; 101(2):e55-8. PMC: 4938334. DOI: 10.3324/haematol.2015.133819. View

10.

Koh Y, Park J, Bae E, Ahn K, Kim I, Bang S . Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. Int J Hematol. 2009; 90(1):1-5. DOI: 10.1007/s12185-009-0350-1. View

11.

Schuurhuis G, Heuser M, Freeman S, Bene M, Buccisano F, Cloos J . Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131(12):1275-1291. PMC: 5865231. DOI: 10.1182/blood-2017-09-801498. View

12.

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E . Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. J Clin Oncol. 2017; 35(11):1223-1230. DOI: 10.1200/JCO.2016.70.4551. View

13.

Cilloni D, Petiti J, Rosso V, Andreani G, Dragani M, Fava C . Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?. Int J Mol Sci. 2019; 20(9). PMC: 6540058. DOI: 10.3390/ijms20092249. View

14.

Gorello P, Cazzaniga G, Alberti F, DellOro M, Gottardi E, Specchia G . Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006; 20(6):1103-8. DOI: 10.1038/sj.leu.2404149. View

15.

Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L . Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352(3):254-66. DOI: 10.1056/NEJMoa041974. View